rifampicin + isoniazid + pyrazinamide + ethambutol (Sanofi)

Rifafour e-275 is a fixed-dose combination (FDC) oral tablet containing four first-line antituberculosis agents: rifampicin (150 mg), isoniazid (75 mg), pyrazinamide (400 mg), and ethambutol hydrochloride (275 mg), with sodium ascorbate included as an antioxidant. It is indicated for the initial phase treatment of pulmonary and extrapulmonary tuberculosis in new adult patients and for the re-treatment of adult cases. The combination targets *Mycobacterium tuberculosis* through multiple pathways: rifampicin inhibits DNA-dependent RNA polymerase; isoniazid inhibits the synthesis of mycolic acids essential for the mycobacterial cell wall; pyrazinamide disrupts membrane potential and transport; and ethambutol inhibits arabinosyl transferase, interfering with cell wall biosynthesis. This FDC is designed to simplify treatment regimens, improve patient adherence, and reduce the risk of developing drug-resistant tuberculosis. It is a registered trademark of Sanofi.

Brand names

Rifafour e-275Rifafour

Other names

RHZE4-FDC TB treatment